Erasca (ERAS) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and strategy

• Focused on erasing cancer by targeting the RAS/MAPK kinase pathway through three complementary approaches: upstream/downstream nodes, direct RAS targeting, and escape route inhibition.

• Built a leading portfolio with assets like naporafenib (pan-RAF inhibitor), ERAS-0015 (pan-RAS molecular glue), and ERAS-4001 (pan-KRAS inhibitor).

• Prioritizes ERAS-0015, ERAS-4001, and naporafenib based on potential impact and commercial opportunity.

• Pipeline expansion driven by external innovation, with eight deals in four years, leveraging team expertise and creative deal-making.

• Raised over $250 million in Q2 2023, supporting runway into H1 2027.

Pipeline and clinical development

• ERAS-0015 and ERAS-4001 acquired in May 2023, with IND filings planned for H1 2024 and phase 1 data expected in 2026.

• ERAS-0015 shows superior in vitro and in vivo potency, better PK/ADME properties, and potentially improved safety profile compared to competitors.

• Naporafenib, in-licensed from Novartis, is the most advanced pan-RAF inhibitor, with pivotal SEACRAFT-2 study in NRAS melanoma and SEACRAFT-1 in RAS Q61X solid tumors.

• SEACRAFT-2 is a phase III, two-stage trial with a randomized readout expected in 2025.

• ERAS-0012, a bispecific EGFR antibody, is progressing internally, targeting both active and inactive EGFR conformations.

Market opportunity and competitive landscape

• RAS/MAPK pathway implicated in up to half of all solid tumors, representing a large market, especially in CRC, pancreatic, and lung cancers.

• Naporafenib's peak sales estimated at $1 billion PAN, with melanoma contributing several hundred million.

• Multiple players expected in the RAS space, with room for differentiation based on efficacy, safety, and target selectivity.

• Pan-RAS and pan-KRAS assets provide flexibility for combination strategies and address different tumor histologies.

• IP position for ERAS-0015 is strong, with patent life to 2043 and a competitive but challenging chemistry landscape.